In This Issue
1607 In This Issue of Diabetes Care

Commentaries
1609 Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions J.M. O’Connell and S.M. Manson

1612 Health Insurance for Diabetes Prevention Confers Health Benefits and Breaks Even on Cost Within 2 Years M.B. Weber and K.M.V. Narayan

Diabetes Care Symposium
1615 Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground P. Home

1624 The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes S.F.A. Grant

Clinical Care/Education/Nutrition/Psychosocial Research
1630 Decreasing Trends in Mean HbA1c Are Not Associated With Increasing Rates of Severe Hypoglycemia in Children: A Longitudinal Analysis of Two Contemporary Population-Based Pediatric Type 1 Diabetes Registries From Australia and Germany/Austria Between 1995 and 2016 A. Haynes, J.M. Hermann, H. Clapin, S.E. Hofer, B. Karges, T.W. Jones, E.A. Davis, and R.W. Holt, for the WACDD and DPV registries

1637 Disturbed Eating Behaviors in Adolescents and Emerging Adults With Type 1 Diabetes: A One-Year Prospective Study K. Luyckx, M. Verschueren, N. Palmero, E.R. Goethals, I. Weerts, and L. Claes


Epidemiology/Health Services Research

1669 Association of Anxiety With High-Cost Health Care Use Among Individuals With Type 2 Diabetes E. Iturralde, F.W. Chi, R.W. Grant, C. Weisner, L. Van Dyke, A. Pruzansky, S. Bui, P. Madvig, R. Pearl, and S.A. Sterling

1675 Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer–Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study J. Cho, R. Scragg, S.J. Pandol, M.O. Goodarzi, and M.S. Petrov

1684 Age, HLA, and Sex Define a Marked Risk of Organ-Specific Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes C. Winkler, M. Jolink, A. Kaafy, N.A. Kwarteng, P. Achenbach, E. Bonifacio, and A.-G. Ziegler

1692 Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes J. Guo, M.M. Brooks, M.F. Muldoon, A.I. Naimi, T.J. Orchard, and T. Costacou

1700 Educational and Health Outcomes of Children Treated for Type 1 Diabetes: Scotland-Wide Record Linkage Study of 766,047 Children M. Fleming, C.A. Fitzton, M.F.C. Steiner, J.S. McIay, D. Clark, A. King, R.S. Lindsay, D.F. Mackay, and J.P. Pell


Emerging Therapies: Drugs and Regimens

1724 PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes V.R. Aroda, J. Rosenstock, Y. Terauchi, Y. Altuntas, N.M. Lalic, E.C. Morales Villegas, O.K. Jeppesen, E. Christiansen, C.L. Hertz, and M. Haluzik, for the PIONEER 1 Investigators


Pathophysiology/Complications
1742 Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes The RISE Consortium


1760 Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes S. Pilemann-Lyberg, D.G.K. Rasmussen, T.W. Hansen, N. Tofte, S.A. Winther, S. Holm Nielsen, S. Theilade, M.A. Karasal, F. Genovesi, and P. Rossing

Keep up with the latest information for Diabetes Care and other ADA titles via Facebook (@ADAJournals) and Twitter (@ADA_Journals).

All articles in Diabetes Care are available online at diabetes.org/diabetescare. Cover articles and select content are available free of charge. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

ADA’s Diabetes Core Update podcasts are available at diabetesjournals.org and through iTunes.

**Cardiovascular and Metabolic Risk**

1776 Effect on Health Care Expenditures During Nationwide Implementation of the Diabetes Prevention Program as a Health Insurance Benefit

1784 A Genome-Wide Association Study Identifies Blood Disorder–Related Variants Influencing Hemoglobin A1c With Implications for Glycemic Status in U.S. Hispanics/Latinos

1792 Microvascular Disease in Patients With Diabetes Without Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction

1800 Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk

1809 Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

1816 Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study
T. Du, C. Fernandez, R. Barshop, V. Fonseca, W. Chen, and L.A. Bazzano

1824 Associations of Perfluoroalkyl and Polyfluoroalkyl Substances With Incident Diabetes and Microvascular Disease

**Novel Communications in Diabetes**

1833 Lifestyle Counseling and Long-term Clinical Outcomes in Patients With Diabetes
H. Zhang, S.I. Goldberg, N. Hosomura, M. Shubina, D.C. Simonson, M.A. Testa, and A. Turchin

**Issues and Events**

1837 Issues and Events

**e-Letters – Observations**

e141 Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide: Unveiling Anaphylaxis to Glucagon-Like Peptide 1 Receptor Agonists
O. Shamriz, A. NaserEddin, O. Mosenzon, S. Svir, and Y. Tal

e143 Diabetes During Pregnancy Modifies the Association Between Birth Weight and Education: A Whole-of-Population Study
L.G. Smithers, M.N. Mittlein, G. Dekker, B.W. Mol, and J. Lynch

e146 Proteinuria and Risk of Lower-Extremity Amputation in Patients With Peripheral Artery Disease

e148 Prospective Associations of Waist-to-Height Ratio With Cardiovascular Events in Postmenopausal Women: Results From the Women’s Health Initiative

e150 Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes

e153 Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab
B. Trinh, M.Y. Donath, and H. Laubli

**e-Letters – Comments and Responses**

e155 Comment on Elliott et al. Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up. Diabetes Care 2019;42:1290–1296
J. Milei, F. Azzato, and G.A. Rodriguez-Granillo

e156 Response to Comment on Elliott et al. Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up. Diabetes Care 2019;42:1290–1296